Radical hysterectomy for FIGO stage IIB cervical cancer: Clinicopathological characteristics and prognostic evaluation

Kasamatsu, Takahiro; Onda, Takashi; Sawada, Morio; Kato, Tomoyasu; Ikeda, Shun‐ichi

doi:10.1016/j.ygyno.2009.03.026

Cited by 38 publications

(41 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study evaluating patients with stage IB-IIB cervical carcinomas treated by surgery, Trattner et al found only lymph node metastases and histopathological staging to be independent prognostic factors for OS in multivariate analysis (Trattner et al, 2001). In patients with stage IIB cervical carcinoma performed radical hysterectomy, Kasamatsu et al found the presence of lymph node metastasis as an independent prognostic factor in multivariate analysis (Kasamatsu et al, 2009). Similarly, positive lymph node involvement was an independent prognostic factor in multivariate analysis for OS in our study.…”

Section: Survival Outcomessupporting

confidence: 81%

Lack of any Impact of Histopathology Type on Prognosis in Patients with Early-Stage Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix

Teke¹,

Yöney²,

Teke³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Multivariate analysis using a Cox-proportional hazards model was used to adjust for prognostic factors and to estimate hazard ratio (HR) with 95% confidence interval (CI). Results:There was no differences between the two tumour types in age, stage, pelvic nodal metastasis, parametrial invasion, surgical margin status, DSI, LVSI, maximal tumor diameter, grade, and treatment modalities. 5-year OS and DFS were 73% and 77%, versus 64% and 69%, for SCC and adenocarcinoma, respectively (p> 0.05). Multivariate analysis revealed independent prognostic factors including pelvic nodal metastasis and resection margin status for OS (p=0.008, p=0.002, respectively). Conclusions: Prognosis of FIGO stage IA-IIB cervical cancer patients was found to be the same for those with adenocarcinoma and SCC.

show abstract

Section: Survival Outcomessupporting

confidence: 81%

Lack of any Impact of Histopathology Type on Prognosis in Patients with Early-Stage Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix

Teke¹,

Yöney²,

Teke³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…In previous decades, surgeries had commonly been performed on patients with stage IIB cancer, whereas today surgeries for stage IIB cancer are performed only at highly specialized institutes. Surgical treatment for FIGO stage IIB cervical cancer is still quite common in Japan, China, and South Korea [40,[64][65][66][67] . Recently, radical hysterectomy with adjuvant radiotherapy for the treatment of FIGO stage IIB cervical cancer has been recommended by the German Cancer Society (DKG) and the German Society of Gynecology and Obstetrics (DGGG) [68] .…”

Section: Discussionmentioning

confidence: 99%

Prognostic Parameters for Patients with Cervical Cancer FIGO Stages IA2-IIB: A Long-Term Follow-Up

Obrzut¹,

Semczuk

Naróg

et al. 2017

Oncology

View full text Add to dashboard Cite

Objective: We assessed the prognostic factors related to 10-year overall survival and disease-free survival in cervical cancer patients that underwent primary surgical protocols in 1 institution. Materials and Methods: A total of 102 patients with uterine cervical cancer at FIGO stages IA2-IIB that underwent a Piver type III radical hysterectomy and pelvic lymphadenectomy between 1998 and 2001 were included. Univariate and multivariate analyses of 10-year overall survival and 10-year disease-free survival were performed. Results: Univariate analysis revealed that only lymphovascular space invasion significantly affected 10-year overall survival (p = 0.04), but it had no effect on the 10-year disease-free survival rate. Multivariate analysis demonstrated that survival rates were significantly affected by FIGO stage (p = 0.02, 95% CI: 1.18-5.55, for 10-year overall survival; p = 0.03, 95% CI: 1.07-6.12, for 10-year disease-free survival) and metastases to the pelvic lymph nodes (p = 0.0005, 95% CI: 1.81-8.53, for 10-year overall survival; p = 0.01, 95% CI: 1.26-7.24, for 10-year disease-free survival). Conclusions: The only independent prognostic factors for 10-year survival rates in patients with cervical cancer at FIGO stages IA2-IIB were clinical stage and presence of metastases to the pelvic lymph nodes. The presence of lymphovascular space invasion adversely affected 10-year overall survival.

show abstract

“…16,17 Kasamatsu et al 18 reported that the 5-year OS is reduced by as much as 50% to 60% depending on the number of node metastasis sites in cervical cancer. Tsai et al 19 also verified that the 5-YSR of patients with 1 positive node site (84%) was statistically different from that of patients with more than 1 site (61%).…”

Section: Discussionmentioning

confidence: 99%

Significance of the Absolute Number and Ratio of Metastatic Lymph Nodes in Predicting Postoperative Survival for the International Federation of Gynecology and Obstetrics Stage IA2 to IIA Cervical Cancer

Chen

Zhang

Tian

et al. 2013

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

Radical hysterectomy for FIGO stage IIB cervical cancer: Clinicopathological characteristics and prognostic evaluation

Cited by 38 publications

References 22 publications

Lack of any Impact of Histopathology Type on Prognosis in Patients with Early-Stage Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix

Lack of any Impact of Histopathology Type on Prognosis in Patients with Early-Stage Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix

Prognostic Parameters for Patients with Cervical Cancer FIGO Stages IA2-IIB: A Long-Term Follow-Up

Significance of the Absolute Number and Ratio of Metastatic Lymph Nodes in Predicting Postoperative Survival for the International Federation of Gynecology and Obstetrics Stage IA2 to IIA Cervical Cancer

Contact Info

Product

Resources

About